Find research datasets worth reusing

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

ClinicalTrials.gov study NCT05650749. IPD Sharing: NO. Countries: 1. Publications: 1.

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

ClinicalTrials.gov study NCT00410631. IPD Sharing: Not stated. Countries: 2. Publications: 1.

Surgery in Treating Children With Neuroblastoma

ClinicalTrials.gov study NCT00003119. IPD Sharing: Not stated. Countries: 7. Publications: 1.

Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells

ClinicalTrials.gov study NCT03242603. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma

ClinicalTrials.gov study NCT01174537. IPD Sharing: Not stated. Countries: 1. Publications: 8.

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

ClinicalTrials.gov study NCT00107289. IPD Sharing: Not stated. Countries: 1. Publications: 2.

Racotumomab in Patients With High-risk Neuroblastoma

ClinicalTrials.gov study NCT02998983. IPD Sharing: NO. Countries: 1. Publications: 0.

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

ClinicalTrials.gov study NCT00017368. IPD Sharing: Not stated. Countries: 2. Publications: 5.

publicOct 2019View details →

dryad32/100

The ganglioside, GD2, as a circulating tumor biomarker for neuroblastoma

Open the record for dataset details and reuse information.

dryad28/100

Data from: Acute maneb exposure significantly alters both glycolysis and mitochondrial function in neuroblastoma cells

The pesticides paraquat (PQ) and maneb (MB) have been described as environmental risk factors for Parkinson's disease (PD), with mechanisms associated with mitochondrial dysfunction and reactive oxygen species generation. A combined exposure of PQ and MB in murine models and neuroblastoma cells has been utilized to further advance understanding of the PD phenotype. MB acts as a redox modulator through alkylation of protein thiols and has been previously characterized to inhibit complex III of the electron transport chain and uncouple the mitochondrial proton gradient. The purpose of this study was to analyze ATP-linked respiration and glycolysis in human neuroblastoma cells utilizing the Seahorse extracellular flux platform. Employing an acute, subtoxic exposure of MB, this investigation revealed a MB-mediated decrease in mitochondrial oxygen consumption at baseline and maximal respiration, with inhibition of ATP synthesis and coupling efficiency. Additionally, MB-treated cells showed an increase in nonmitochondrial respiration and proton leak. Further investigation into mitochondrial fuel flex revealed an elimination of fuel flexibility across all 3 major substrates, with a decrease in pyruvate capacity as well as glutamine dependency. Analyses of glycolytic function showed a substantial decrease in glycolytic acidification caused by lactic acid export. This inhibition of glycolytic parameters was also observed after titrating the MB dose as low as 6 μM, and appears to be dependent on the dithiocarbamate functional group, with manganese possibly potentiating the effect. Further studies into cellular ATP and NAD levels revealed a drastic decrease in cells treated with MB. In summary, MB significantly impacted both aerobic and anaerobic energy production; therefore, further characterization of MB's effect on cellular energetics may provide insight into the specificity of PD to dopaminergic neurons.

opencc-zeroDec 2017View details →

zenodo28/100

Influence of Yokukansan on refractive index of neuroblastoma cells - dataset

This dataset contains 3 sets with files connected to holographic tomography (HT), fluorescence microscopy (FM) and Raman micro-spectroscopy (RmS) measurements. All measurements are from experiment on SH-SY5Y neuroblastoma cells with treatement of diferent doses of Yokukansan (YKS - Chinses herbal medicine herb). Measurements were carried out in Nencki Institute of Experimental Biology and University of Warsaw.  For HT: All files are *.mat files HT_3D_RI - in the file there are values of RI of cells (named in order: "RI3D_DoseTime" for ex. "RI3D_1mg25h")  HT_LD_volumes - in the file, there are values of LD volumes and whole cell volumes for cells (named in order: "LD_DoseTime" for ex. "LD_1mg25h") For FM: File is an *.xlsx In the file there is a spreadsheet with data of mean intensity of Hoechst staining signal in cells measured with FM.  There are results from 3 repetition of the experiment (Day 1, 2, 3). In one experiment there were measurements of 8 doses (0,5, 1, 2, 4, 5, 6, 7, 8, mg/ml) in 4 time points (after 24h, 48h, 72h, 6 days). There is also control measurement values for each day. For RmS: There are three *.npy files and one *.txt *.npy files containing the raw hyperspectral cube of the SH-SY5Y neuroblastoma cells in the form of the numpy three-dimensional array (named in order: "RmS_DoseTime" for ex. "RmS_4mg24h"). Two first dimensions correspond to the spatial position of the recorded spectra and the last one contains intensities for the Raman shift range. The measurement was performed with spatial resolution of 0.5 µm. Information about the Raman shift values for which the spectra were recorded can be found in the Raman_shift_values.txt file.  Code example: import numpy as np hypespectral_cube = np.load('control.npy')   # Loading the data R_shifts = np.loadtxt('Raman_shift_values.txt') # vector of Raman shifts single_spectrum = hypespectral_cube[x,y,:] # gives Raman intensity recorded at x*0.5 µm, y*0.5 µm position.  intensity_map = hypespectral_cube[:,:,Rshift_index] # gives the intensity image for the specific Raman shift value defined by R_shifts[Rshift_index]

opencc-by-4.0Nov 2022View details →

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

ClinicalTrials.gov study NCT01505608. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

ClinicalTrials.gov study NCT03189706. IPD Sharing: YES. Countries: 1. Publications: 0.

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

ClinicalTrials.gov study NCT04753658. IPD Sharing: NO. Countries: 6. Publications: 0.

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

ClinicalTrials.gov study NCT01747876. IPD Sharing: NO. Countries: 5. Publications: 0.

Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma

ClinicalTrials.gov study NCT03503864. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma

ClinicalTrials.gov study NCT04560166. IPD Sharing: Not stated. Countries: 2. Publications: 0.

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

ClinicalTrials.gov study NCT04238819. IPD Sharing: YES. Countries: 8. Publications: 0.

A Study of N9 Chemotherapy in Children With Neuroblastoma

ClinicalTrials.gov study NCT04947501. IPD Sharing: YES. Countries: 1. Publications: 0.

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

ClinicalTrials.gov study NCT06831552. IPD Sharing: YES. Countries: 1. Publications: 0.